PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics, a clinical-stage biotech firm, has issued options as part of its strategy to advance a new generation of RNA therapies for genetic diseases. The company, a pioneer in drug development for blinding eye diseases, has granted 21 million options with a $0.17 exercise price, set to expire in May 2028, with specific vesting conditions tied to continued service relationships over a three-year period. These efforts support their ongoing programs, with human trials for eye and kidney diseases expected to start between mid-2024 and early 2025.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
